Ultragenyx shares tumble lower after rare disease drug fails PhII trial
Shares of Ultragenyx $RARE tumbled close to 10% after the rare disease biotech reported that one of its drugs failed a Phase II trial.
UX007 was tested as a treatment for glucose transporter type-1 deficiency syndrome—or Glut1 DS—among a small group of patients. But it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
